We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.385 | 2.21 | 2.39 | 12,509 | 08:53:06 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -2.09 | 7.93M |
TIDMIMM
RNS Number : 1388X
Immupharma PLC
04 May 2016
4 MAY 2016
ANNUAL REPORT AND ACCOUNTS
NOTICE OF ANNUAL GENERAL MEETING: 26 MAY 2016
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2015 has been posted to shareholders.
The Annual Report will be available later today, in electronic form, for download on the Company's website www.immupharma.org.
The Company's Annual General Meeting will be held on Thursday 26 May 2016 at 10:00am at the offices of Bircham Dyson Bell LLP, 50 Broadway, London, SW1H 0BL.
-Ends- For further information please contact: ImmuPharma plc (www.immupharma.org) + 44 (0) 20 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations Twitter: @immupharma + 44 (0) 7721 413496 Panmure, Gordon (UK) Limited, NOMAD & Broker +44 (0) 20 7886 2500 Fred Walsh / Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACSSSLFWDFMSELI
(END) Dow Jones Newswires
May 04, 2016 02:01 ET (06:01 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions